The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
DATROWAY AstraZeneca Pty Ltd
Product name
DATROWAY
Sponsor
Accepted date
May-2024
Active ingredients
datopotamab deruxtecan
Proposed indication
For the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy.
Application type
A (new medicine)
Publication date
May-2024